2nd PRESTIGIO Registry meetING on HIV multidrug resistance

Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population.

Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population.

Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population.

Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population.

Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population.

Razionale Scientifico | 2nd PRESTIGIO Registry meetING on HIV...

Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population.

According to more recent Italian epidemiological data, the prevalence of multidrug resistance - MDR - [defined as at least one major resistant mutation in at least three different drug classes among NRTIs, NNRTIs, PIs and integrase strand transfer inhibitors (INSTIs)] among ART-experienced subjects with HIV was estimated at approximately 9% in the period 2011–2018. Individuals with multidrug-resistant (MDR) strains are usually characterized by a complex clinical history with previous or current uncontrolled viral replication, determining adaptive immune response depletion and occurrence of opportunistic infections. 

PRESTIGIO Registry, the observational, prospective, multicentre study, serves as a basis for evaluating the long-term effectiveness of antiretroviral therapies, the evolution of genotypic and phenotypic susceptibility to antiretroviral drugs, (particularly novel drugs being developed for highly treatment experienced patients – HTE - often harbouring multidrug resistant virus), the determinants of clinical outcomes including virological/immunological/inflammatory markers, and the incidence of AIDS related conditions and comorbidities.

This 2^nd National Registry Meeting (RING)  is designed as a forum involving the PRESTIGIO Network of specialists as well as basic scientists and clinicians experienced in the management of this fragile population: the program  will include some key lectures hold by experts in the field interspersed with plenary discussion groups on challenging clinical experiences, so as to improve interaction and participation among attendees.